A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease

2018 ◽  
Vol 68 ◽  
pp. S819
Author(s):  
R. Forlano ◽  
B.H. Mullish ◽  
N. Katertsidis ◽  
N. Giannakeas ◽  
A. Tzallas ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Mobile Application ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0224474
Author(s):  
Madunil Anuk Niriella ◽  
Anuradhani Kasturiratna ◽  
Thulani Beddage ◽  
Dileepa Senajith Ediriweera ◽  
Shamila Thivanshi De Silva ◽  
...  
Keyword(s):  
Liver Disease ◽  
General Population ◽  
Fatty Liver ◽  
Prospective Cohort ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Follow Up Study ◽  
Alcoholic Fatty Liver Disease

scholarly journals Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease

2018 ◽  
Vol 7 (11) ◽  
pp. 378 ◽  
Author(s):  
Daniele Pastori ◽  
Francesco Baratta ◽  
Marta Novo ◽  
Nicholas Cocomello ◽  
Francesco Violi ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Density Lipoprotein ◽  
Alcoholic Fatty Liver ◽  
Remnant Lipoprotein ◽  
Cerebrovascular Events ◽  
Alcoholic Fatty Liver Disease

: Non-alcoholic fatty liver disease (NAFLD) is characterized by an atherogenic dyslipidaemia and an increased cardiovascular risk. Remnant lipoprotein cholesterol (RLP-C) is emerging as a novel cardiovascular risk factor, but its predictive value in patients with NAFLD is unknown. We investigated factors affecting RLP-C levels, and the association with major adverse cardiovascular and cerebrovascular events (MACCE) in NAFLD. A prospective observational cohort study was carried out including 798 unselected patients with cardio-metabolic diseases screened by ultrasound for the presence of NAFLD. Fasting RLP-C (mg/dL) was calculated as total cholesterol—(HDL (high-density lipoprotein) + LDL (low-density-lipoprotein)). Primary endpoint of the follow-up study was a combined endpoint of MACCE. Patients with NAFLD (79.2%) had higher median fasting RLP-C in comparison to those without (27.0 vs. 20.0 mg/ dL, respectively p < 0.001). Metabolic syndrome, NAFLD, age above median, and female sex were independently associated to fasting RLP-C above the median. In patients with NAFLD, values of RLP-C were associated with liver disease severity, as shown by the increasing value of RLP-C across tertiles of aspartate aminotransferase (AST) (p = 0.002) and gamma-glutamyl transpeptidase (GGT) (p < 0.001). Furthermore, levels of RLP-C and Hamaguchi score, were significantly correlated (r = 0.193, p < 0.001). During a median follow-up of 32 months (interquartile range: 14.2–51.7, 1700 person-years), 41 MACCE (2.41%/year) were registered in 596 NAFLD patients. The rate of events was higher in NAFLD patients with RLP-C above the median compared to those below (log-rank test p = 0.040). Age (hazard ratio (HR) 1.039, 95% confidence interval (CI), 1.005–1.074, p = 0.024), previous cardiovascular events (HR 2.210, 95% CI, 1.052–4.643, p = 0.036), female sex (HR 0.454, 95% CI, 0.208–0.989, p = 0.047) and RLP-C above the median (HR 2.202, 95% CI, 1.132–4.285, p = 0.020) were associated with MACCE. In conclusion, we found that NAFLD was independently associated with higher circulating RLP-C, and that high RLP-C levels were predictive of MACCE in patients with NAFLD.

Impact of Weight Regain on the Evolution of Non-alcoholic Fatty Liver Disease After Roux-en-Y Gastric Bypass: a 3-Year Follow-up

2018 ◽  
Vol 28 (10) ◽  
pp. 3131-3135 ◽  
Author(s):  
Laísa Simakawa Jimenez ◽  
Fábio Henrique Mendonça Chaim ◽  
Felipe David Mendonça Chaim ◽  
Murillo Pimentel Utrini ◽  
Martinho Antonio Gestic ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Weight Regain ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals The Impact of Combined Bariatric Interventions on the Course of Non-Alcoholic Fatty Liver Disease

2021 ◽  
Vol 14 (2) ◽  
pp. 92-106
Author(s):  
Aleksandra Igorevna Mitsinskaya ◽  
Vladimir Viktorovich Evdoshenko ◽  
Mikhail Borisovich Fishman ◽  
Alexey Yurievich Sokolov ◽  
V. Sergeevich Samoilov ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Mini Gastric Bypass ◽  
Liver Size ◽  
Alcoholic Fatty Liver ◽  
The Impact ◽  
Alcoholic Fatty Liver Disease

Background. Obesity is widely recognized as a disease that acquires the scale of an epidemic and is accompanied by a number of comorbidities, one of which is non-alcoholic fatty liver disease (NAFLD), while the issue of the impact of bariatric interventions on its course remains a subject of discussion, which determines the relevance of this study.Aims. Тo evaluate the impact of combined bariatric interventions - laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic mini-gastric bypass (LMGB-OAGB), - on the course of NAFLD and to determine the criteria that affect the dynamics of NAFLD after thеsе bariatric interventions.Materials and methods. The study included 56 patients who had one of 2 types of bariatric interventions performed between 2014 and 2017: LRYGB (26 (46,4%) patients) and LMGB-OAGB (30 (53,6%) patients). All patients underwent intraoperative liver biopsy, a range of laboratory and instrumental studies, FibroTest were calculated in dynamics. The frequency of complications in the postoperative period was estimated. The period of observation was 2 years. Results. In the group of laparoscopic Roux-en-Y gastric bypass 12 (46.2%) patients showed signs of liver fibrosis according to histological research, and 8 (30.8%) - signs of non - alcoholic steatohepatitis (NASH). There was an increase in transaminases in 5(19,2%), gamma-glutamyltranspeptidase (GGTP) in 19 (73.1%), and total bilirubin in 8 (30.8%) subjects. 20 (76.9%) participants had increased alkaline phosphatase (ALP), 22 (84.6%) had reduced high density lipoproteins (HDL) and increased triglycerides (TG). According to the results of ultrasound examination of the liver, 19 (73.1%) patients had enlarged liver size, 26 (100%) - diffuse heterogeneity, and 25 (96.2%) - hyperechogenicity. In the group of laparoscopic mini-gastric bypass, there were signs of liver fibrosis in 14 (46.7%) and NASH - in 14 (46.7%) patients. An increase in tranasminases was observed in 8 (26.7%), GGTP in 22 (73.3%), and total bilirubin in 6 (20%) patients. 9 (30%) of participants had increased ALP, 26 (86.7%) patients had reduced HDL and increased TG. 21 (70%) patients had enlarged liver size, 29 (96.7%) - diffuse heterogeneity, and 28 (93.3%) - hyperechogenicity.6 months after both types of interventions, there was a decrease in the clinical and biochemical characteristics of non-alcoholic fatty liver disease, which was transient and regressed by 1 year after surgery.After laparoscopic Roux-en-Y gastric bypass %EBMIL in 1 year was 75.25 [65.85-84.36] %. Normalization of transaminases was observed in 84.6%, cholestasis indicators in 87.2%, and FibroTest -in 46.2% of cases. % EBMIL 1 year after laparoscopic mini-gastric bypass was 74.77 [67.28-78.89] %. Normalization of transaminases was observed in 83.3%, cholestasis indicators in 78.9%, and FibroTest -in 43.3% of cases.Combined bariatric interventions were shown to be more effective in participants under 45 years of age compared to those over 45 years of age and in patients with initial stages of fibrosis F0-F2 by METAVIR compared to participants with stages F3-F4 by METAVIR. Patients with a BMI of more than 40 kg / m2 achieved higher FibroTest values after six months compared to subjects with a BMI of up to 40 kg/m2 and in fewer cases - FibroTest normalization by 1 year after surgery, respectively. The effectiveness of operations on the course of NAFLD was comparable.The results of the intervention on signs of non-alcoholic fatty liver disease were preserved for 2 years of postoperative follow-up. The mortality rate during the entire follow-up period was 0%. 47 (83,9%) patients were followed up to 2 years.Conclusion. Тhere was a high efficiency of RYGB and MGB-OAGB in patients with non-alcoholic fatty liver disease, while a transient aggravation of the course of non-alcoholic fatty liver disease was detected 6 months after the operation.Keywords: non-alcoholic fatty liver disease; obesity; metabolic syndrome; bariatric surgery; LRYGB; LMGB-OAGB; FibroTest; surgical intervention

scholarly journals Modern view of the importance of cholecystectomy in the prognosis of a patient with non-alcoholic fatty liver disease: follow-up algorithm and therapeutic approaches

2021 ◽  
Vol 5 (6) ◽  
pp. 438-445
Author(s):  
S.N. Mekhtiev ◽  
◽  
O.A. Mekhtieva ◽  
M.V. Ukhova ◽  
Z.M. Ibragimova ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Therapeutic Approaches ◽  
Alcoholic Fatty Liver ◽  
Strict Adherence ◽  
Modern View ◽  
Alcoholic Fatty Liver Disease

The gallbladder is an organ that plays an important role in maintaining effective enterohepatic circulation (EHC) of bile and preserving the metabolic homeostasis of lipids and bile acids. Despite modern ideas about the role of the gallbladder in the human body, especially in subjects with metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), cholecystectomy (CE) remains one of the most common surgeries, including in this patient category. The review examines the following in patients with NAFLD: the gallbladder role, the association between NAFLD and cholelithiasis (C), indications for CE, as well as the consequences of this intervention. The authors discuss the issues of patient management with NAFLD after CE. Patients with C and NAFLD who have undergone CE need a number of diagnostic measures aimed at identifying and timely correction of disorders, as well as complex treatment, which includes the risk factors elimination, strict adherence to diet, exercise regime, the use of drugs improving the EHC state, lipid and carbohydrate metabolism, the metabolic function of hepatocytes and inhibiting the liver fibrogenesis. KEYWORDS: cholecystectomy, non-alcoholic fatty liver disease, cholelithiasis, ursodeoxycholic acid, metabolic syndrome, insulin resistance. FOR CITATION: Mekhtiev S.N., Mekhtieva O.A., Ukhova M.V., Ibragimova Z.M. Modern view of the importance of cholecystectomy in the prognosis of a patient with non-alcoholic fatty liver disease: follow-up algorithm and therapeutic approaches. Russian Medical Inquiry. 2021;5(6):438–445 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-438-445.

Sign in / Sign up

Export Citation Format

Share Document